The role of acute combined peroxisome proliferator-activated receptors alpha and gamma stimulation on insulin action in humans

Trial Profile

The role of acute combined peroxisome proliferator-activated receptors alpha and gamma stimulation on insulin action in humans

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Eicosapentaenoic acid; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 30 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 07 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Mar 2012 Additional lead trial centre and investigator (Meredith Hawkins) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top